Total Valuation
CombiGene AB has a market cap or net worth of €4.13M. The enterprise value is €38.38.
Market Cap€4.13M
Enterprise Value€38.38
Share Statistics
CombiGene AB has 19,801,197 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding19,801,197
Owned by Insiders―
Owned by Institutions―
Financial Efficiency
CombiGene AB’s return on equity (ROE) is -0.22 and return on invested capital (ROIC) is -23.38%.
Return on Equity (ROE)-0.22
Return on Assets (ROA)-0.22
Return on Invested Capital (ROIC)-23.38%
Return on Capital Employed (ROCE)-0.23
Revenue Per Employee0.00
Profits Per Employee-12.98M
Employee Count1
Asset Turnover0.00
Inventory Turnover0.00
Valuation Ratios
The current PE Ratio of CombiGene AB is 38.9. CombiGene AB’s PEG ratio is 0.05.
PE Ratio38.9
PS Ratio0.00
PB Ratio0.81
Price to Fair Value0.81
Price to FCF-3.50
Price to Operating Cash Flow-18.69
PEG Ratio0.05
Income Statement
In the last 12 months, CombiGene AB had revenue of 0.00 and earned -12.36M in profits. Earnings per share was -0.62.
Revenue0.00
Gross Profit-8.16M
Operating Income-12.98M
Pretax Income-12.36M
Net Income-12.36M
EBITDA-7.19M
Earnings Per Share (EPS)-0.62
Cash Flow
In the last 12 months, operating cash flow was -2.57M and capital expenditures 0.00, giving a free cash flow of -2.57M billion.
Operating Cash Flow-2.57M
Free Cash Flow-2.57M
Free Cash Flow per Share-0.13
Dividends & Yields
CombiGene AB pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta0.44
52-Week Price Change1.27%
50-Day Moving Average0.15
200-Day Moving Average―
Relative Strength Index (RSI)54.15
Average Volume (3m)0.00
Important Dates
CombiGene AB upcoming earnings date is Feb 12, 2027, TBA (Confirmed).
Last Earnings DateAug 21, 2026
Next Earnings DateFeb 12, 2027
Ex-Dividend Date―
Financial Position
CombiGene AB as a current ratio of 5.37, with Debt / Equity ratio of 0.00%
Current Ratio5.37
Quick Ratio5.37
Debt to Market Cap0.00
Net Debt to EBITDA0.36
Interest Coverage Ratio-156.34
Taxes
In the past 12 months, CombiGene AB has paid 0.00 in taxes.
Income Tax0.00
Effective Tax Rate0.00
Enterprise Valuation
CombiGene AB EV to EBITDA ratio is -5.87, with an EV/FCF ratio of -3.30.
EV to Sales0.00
EV to EBITDA-5.87
EV to Free Cash Flow-3.30
EV to Operating Cash Flow-3.30
Balance Sheet
CombiGene AB has €6.17M in cash and marketable securities with €0.00 in debt, giving a net cash position of €6.17M billion.
Cash & Marketable Securities€6.17M
Total Debt€0.00
Net Cash€6.17M
Net Cash Per Share€0.31
Tangible Book Value Per Share€2.80
Margins
Gross margin is -333.96%, with operating margin of 0.00%, and net profit margin of 0.00%.
Gross Margin-333.96%
Operating Margin0.00%
Pretax Margin0.00%
Net Profit Margin0.00%
EBITDA Margin0.00%
EBIT Margin0.00%
Analyst Forecast
The average price target for CombiGene AB is ―, which is 11.43% higher than the current price. The consensus rating is ―
Price Target―
Price Target Upside―
Analyst Consensus―
Analyst Count0
Revenue Growth Forecast―
EPS Growth Forecast―